Pipeline Catalysts in Focus: Social media chatter highlights upcoming data readouts for Recursion Pharmaceuticals' lead assets in familial adenomatous polyposis and solid tumors as potential inflection points later this year. Analysts note the company's AI platform could accelerate target validation if early signals hold. Investors appear split on whether these milestones will overcome broader sector headwinds.
Earnings Pressure Mounts: Recent posts underscore concerns over sharply lower second-quarter revenue and accelerating cash burn, prompting some participants to trim positions. Dilution from share issuance and a distressed Altman Z-score have fueled debate about the sustainability of the current valuation. Others maintain that the technology's long-term potential justifies patience through the volatility.
Technical Levels Watched: Discussion centers on the stock's position near $3.20 to $3.50, with support around recent lows and resistance near the 50-day moving average. High-beta trading around AI-biotech themes keeps sentiment engaged despite mixed institutional signals. Overall market tone reflects a cautious outlook on near-term execution risks.
Note: This discussion summary was generated from an AI condensation of post data.
Recursion Pharmaceuticals Insider Trading Activity
Recursion Pharmaceuticals insiders have traded $RXRX stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $RXRX stock by insiders over the last 6 months:
- BLAKE BORGESON has made 0 purchases and 6 sales selling 330,000 shares for an estimated $1,153,200.
- CHRISTOPHER GIBSON has made 0 purchases and 5 sales selling 200,000 shares for an estimated $666,400.
- NAJAT KHAN (CEO and President) has made 0 purchases and 2 sales selling 51,886 shares for an estimated $179,118.
- NAMANDJE BUMPUS has made 0 purchases and 2 sales selling 8,349 shares for an estimated $28,128.
- BEN R TAYLOR (Chief Financial Officer) sold 7,956 shares for an estimated $26,970
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenues of $7.7M in Q2 2026. This is a decrease of -60.1% from the same period in the prior year.
You can track RXRX financials on Quiver Quantitative's RXRX stock page.
You can access data on RXRX stock through the Quiver Quantitative API.
Recursion Pharmaceuticals Hedge Fund Activity
We have seen 177 institutional investors add shares of Recursion Pharmaceuticals stock to their portfolio, and 173 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NOVO HOLDINGS A/S removed 7,929,835 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $24,344,593
- BLACKROCK, INC. added 7,112,385 shares (+16.5%) to their portfolio in Q2 2026, for an estimated $26,102,452
- STATE STREET CORP added 6,215,492 shares (+21.8%) to their portfolio in Q2 2026, for an estimated $22,810,855
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 4,138,286 shares (+inf%) to their portfolio in Q2 2026, for an estimated $15,187,509
- UBS GROUP AG added 3,845,865 shares (+75.4%) to their portfolio in Q2 2026, for an estimated $14,114,324
- LINGOTTO INVESTMENT MANAGEMENT LLP removed 3,675,077 shares (-62.5%) from their portfolio in Q2 2026, for an estimated $13,487,532
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,263,269 shares (-81.1%) from their portfolio in Q2 2026, for an estimated $11,976,197
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Recursion Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $RXRX recently. We have seen 3 analysts offer price targets for $RXRX in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Vikram Purohit from Morgan Stanley set a target price of $5.5 on 05/14/2026
- Gil Blum from Needham set a target price of $8.0 on 05/07/2026
- Priyanka Grover from JP Morgan set a target price of $10.0 on 04/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
